Heparanase (Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Published	Pages	Publisher	Report code
Jun 2022	60	Global Markets Direct	ASDR-607649

Published: Jun 2022 - Pages : 60 - Publisher : Global Markets Direct - Report code : ASDR-607649

B-Side Pharma Ltd
Beta Therapeutics Pty Ltd
CarboMimetics
HepaRx Ltd
Johnson & Johnson
Leadiant Biosciences Inc
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Zucero Therapeutics Ltd

Heparanase - Pipeline Review, H2 2020

This report can be of interest as well:

Heparanase - Pipeline Review, H2 2020

Published: September, 2020 | Report code: ASDR-565194